Iambic closed a $100 million financing to accelerate AI drug‑discovery platforms (Enchant and NeuralPLexer) and move cancer candidates toward the clinic; investors include Abingworth and Alexandria. Iambic emphasized multimodal clinical prediction and physics‑informed protein‑ligand models to shorten discovery timelines and improve preclinical-to-clinic translation. Solve Therapeutics raised $120 million to advance best‑in‑class antibody‑drug conjugates (ADCs), focusing on proprietary linker technology and payload optimization. The round included strategic support from major pharma and is intended to fund IND-enabling work and clinical progression of ADC candidates. The financings underscore investor appetite for AI-enabled discovery and improved ADC chemistry as companies seek to cut time and cost in drug development and address limitations of earlier ADC generations.